Pure Global AI
NCT06335693Recruiting

Adjuvant Hypofractionated Radiotherapy for Prostate Cancer

Safety and Efficacy Study of Adjuvant Hypofractionated Radiotherapy Following Radical Prostatectomy for Prostate Cancer
Changhai HospitalClinicalTrials.govother
Verified
Study focus
Disease/Condition
Prostate Cancer
Drug/Device/Intervention
Radiotherapy
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Changhai Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
N/A
Start date
Mar 28, 2024
End date
Feb 28, 2027
Enrollment
9 participants
Primary outcome

Incidence of radiotherapy-related gastrointestinal and genitourinary adverse events

Summary

Hypofractionated radiation therapy is a new type of radiotherapy which has been shown to play
 a larger role in the treatment of prostate cancer. The aims of the trial were to evaluate the
 safety and feasibility of adjuvant hypofractionated radiotherapy following radical
 prostatectomy for prostate cancer.

ICD-10 classifications
Malignant neoplasm of prostateHyperplasia of prostateDisorder of prostate, unspecifiedOther disorders of prostateCarcinoma in situ: Prostate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06335693
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06335693 through Pure Global AI's free database. This phase not specified trial is sponsored by Changhai Hospital and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 9 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.